Your Top 50 most-cited badge
A badge for your website, a sentence for your CV, and a permanent page where anyone can check the rank.
The article
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy
Eunice S. Wang, Pau Montesinos, Mark David Minden, Je‐Hwan Lee, Michael Heuser, Tomoki Naoe and 15 more
- Rank
- 37 of 6,257
- Percentile
- top 0.6%
- Where
- Blood, 2022
- Citations
- 141
From the 2022 list, OpenAlex counts as of 2026-10-29.
Prefer not to be listed? The same link lets you withhold your name on every list; the article stays, your name does not. Questions: team@avidnote.com.